| 1 |
Martakis K, Claassen J, Gascon-Bayari J, Goldschagg N, Hahn A, Hassan A, Hennig A, Jones S, Kay R, Lau H, Perlman S, Sharma R, Schneider S, Bremova-Ertl T. Efficacy and Safety of N-Acetyl-l-Leucine in Children and Adults With GM2 Gangliosidoses. Neurology 2023;100:e1072-83. [PMID: 36456200 DOI: 10.1212/WNL.0000000000201660] [Reference Citation Analysis]
|
| 2 |
Saberi-Karimian M, Houra M, Jamialahmadi T, Sarvghadi P, Nikbaf M, Akhlaghi S, Sahebkar A. The Effects of N-Acetyl-L-Leucine on the Improvement of Symptoms in a Patient with Multiple Sulfatase Deficiency. Cerebellum 2022;:1-7. [PMID: 36482027 DOI: 10.1007/s12311-022-01504-2] [Reference Citation Analysis]
|
| 3 |
Strupp M, Brandt T, Dieterich M. Zentrale Schwindelsyndrome. Vertigo - Leitsymptom Schwindel 2022. [DOI: 10.1007/978-3-662-61397-9_3] [Reference Citation Analysis]
|
| 4 |
Strupp M, Brandt T, Dieterich M. Schwindel: ein multisensorisches und häufiges Symptom. Vertigo - Leitsymptom Schwindel 2022. [DOI: 10.1007/978-3-662-61397-9_1] [Reference Citation Analysis]
|
| 5 |
Feil K, Adrion C, Boesch S, Doss S, Giordano I, Hengel H, Jacobi H, Klockgether T, Klopstock T, Nachbauer W, Schöls L, Steiner KM, Stendel C, Timmann D, Naumann I, Mansmann U, Strupp M; ALCAT Study Group. Safety and Efficacy of Acetyl-DL-Leucine in Certain Types of Cerebellar Ataxia: The ALCAT Randomized Clinical Crossover Trial. JAMA Netw Open 2021;4:e2135841. [PMID: 34905009 DOI: 10.1001/jamanetworkopen.2021.35841] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 6 |
Martakis K, Claassen J, Gascon-bayarri J, Goldschagg N, Hahn A, Hassan A, Hennig A, Jones SA, Lau H, Perlman S, Sharma R, Schneider SA, Bremova-ertl T. N-acetyl-L-leucine improves symptoms and functioning in GM2 Gangliosidosis (Tay-Sachs & Sandhoff).. [DOI: 10.1101/2021.09.24.21264020] [Reference Citation Analysis]
|
| 7 |
Bremova-Ertl T, Claassen J, Foltan T, Gascon-Bayarri J, Gissen P, Hahn A, Hassan A, Hennig A, Jones SA, Kolnikova M, Martakis K, Raethjen J, Ramaswami U, Sharma R, Schneider SA. Efficacy and safety of N-acetyl-L-leucine in Niemann-Pick disease type C. J Neurol 2021. [PMID: 34387740 DOI: 10.1007/s00415-021-10717-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 8 |
Naef V, Marchese M, Ogi A, Fichi G, Galatolo D, Licitra R, Doccini S, Verri T, Argenton F, Morani F, Santorelli FM. Efficient Neuroprotective Rescue of Sacsin-Related Disease Phenotypes in Zebrafish. Int J Mol Sci 2021;22:8401. [PMID: 34445111 DOI: 10.3390/ijms22168401] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 9 |
Churchill GC, Strupp M, Factor C, Bremova-Ertl T, Factor M, Patterson MC, Platt FM, Galione A. Acetylation turns leucine into a drug by membrane transporter switching. Sci Rep 2021;11:15812. [PMID: 34349180 DOI: 10.1038/s41598-021-95255-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 10 |
Hegdekar N, Lipinski MM, Sarkar C. N-Acetyl-L-leucine improves functional recovery and attenuates cortical cell death and neuroinflammation after traumatic brain injury in mice. Sci Rep 2021;11:9249. [PMID: 33927281 DOI: 10.1038/s41598-021-88693-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 11 |
Bremova-ertl T, Claassen J, Foltan T, Gascón Bayarri J, Gissen P, Hahn A, Hassan A, Hennig A, Jones S, Kolniková M, Martakis K, Ramaswami U, Sharma R, Schneider S. Acetyl-L-leucine for Niemann-Pick type C – a multi-national, rater-blinded phase II trial.. [DOI: 10.1101/2020.12.22.20248704] [Reference Citation Analysis]
|
| 12 |
Kaya E, Smith DA, Smith C, Morris L, Bremova-Ertl T, Cortina-Borja M, Fineran P, Morten KJ, Poulton J, Boland B, Spencer J, Strupp M, Platt FM. Acetyl-leucine slows disease progression in lysosomal storage disorders. Brain Commun 2021;3:fcaa148. [PMID: 33738443 DOI: 10.1093/braincomms/fcaa148] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 13 |
Bremova-Ertl T, Platt F, Strupp M. Sandhoff Disease: Improvement of Gait by Acetyl-DL-Leucine: A Case Report. Neuropediatrics 2020;51:450-2. [PMID: 32892336 DOI: 10.1055/s-0040-1715486] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 14 |
Churchill GC, Strupp M, Bremova-ertl T, Factor M, Patterson MC, Platt FM, Galione A. Acetylation of L-leucine switches its carrier from the L-amino acid transporter (LAT) to organic anion transporters (OAT).. [DOI: 10.1101/2020.11.12.379701] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 15 |
Kaya E, Smith DA, Smith C, Morris L, Bremova-ertl T, Cortina-borja M, Fineran P, Morten KJ, Poulton J, Boland B, Spencer J, Strupp M, Platt FM. Acetyl-Leucine slows disease progression in lysosomal storage disorders.. [DOI: 10.1101/2020.05.20.105973] [Reference Citation Analysis]
|
